

# Conventional and Bayesian workflows for clinical prediction modelling of severe Covid-19 outcomes based on clinical biomarker test results: **LabMarCS: Laboratory Markers of COVID-19 Severity - Bristol Cohort**

Brian Sullivan<sup>a</sup>, Edward Barker<sup>a</sup>, Philip Williams<sup>c</sup>, Louis MacGregor<sup>a</sup>, Ranjeet Bhamber<sup>a</sup>, Matt Thomas<sup>b</sup>, Stefan Gurney<sup>c</sup>, Catherine Hyams<sup>a,b</sup>, Alastair Whiteway<sup>b</sup>, Jennifer A Cooper<sup>a</sup>, Chris McWilliams<sup>a</sup>, Katy Turner<sup>a</sup>, Andrew W. Dowsey<sup>a</sup>, Mahableshwar Albur<sup>b</sup>

<sup>a</sup>University Of Bristol

<sup>b</sup>Southmead Hospital, North Bristol NHS Trust

<sup>c</sup>University Hospitals Bristol and Weston NHS Trust

## Abstract

We describe several regression models to predict severe outcomes in COVID-19 and challenges present in complex observational medical data. We demonstrate best practices for data curation, cross-validated statistical modelling, and variable selection emphasizing recent Bayesian methods. The study follows a retrospective observational cohort design using multicentre records across National Health Service (NHS) trusts in southwest England, UK. Participants included hospitalised adult patients positive for SARS-CoV 2 during March to October 2020, totalling 843 patients (mean age 71, 45% female, 32% died or needed ICU stay), split into training (n=590) and validation groups (n=253). Models were fit to predict severe outcomes (ICU admission or death within 28-days of admission to hospital for COVID-19, or a positive PCR result if already admitted) using demographic data and initial results from 30 biomarker tests collected within 3 days of admission or testing positive if already admitted. Cross-validation results showed standard logistic regression had an internal validation median AUC of 0.74 (95% Interval [0.62,0.83]), and external validation AUC of 0.68 [0.61, 0.71]; a Bayesian logistic regression (with horseshoe prior) internal AUC of 0.79 [0.71, 0.87], and external AUC of 0.70 [0.68, 0.71]. Variable selection performed using Bayesian predictive projection determined a four variable model using Age, Urea, Prothrombin time and Neutrophil-Lymphocyte ratio, with a median internal AUC of 0.79 [0.78, 0.80], and external AUC of 0.67 [0.65, 0.69]. We illustrate best-practices protocol for conventional and Bayesian prediction modelling on complex clinical data and reiterate the predictive value of previously identified biomarkers for COVID-19 severity assessment.

## 1 Introduction

2 Globally as of 26 April 2023, there have been 764 million  
3 confirmed cases of COVID-19, including 6.9 million deaths,  
4 with 24.6 million cases in the UK, resulting in over 207,000  
5 deaths (WHO Coronavirus (COVID-19) Dashboard, <https://covid19.who.int/>). COVID-19 has a wide spectrum of  
6 clinical features ranging from asymptomatic to severe systemic  
7 illness with a significant attributable mortality, while clinical  
8 manifestations are variable especially in the most vulnerable  
9 groups and immunocompromised people [1]. COVID-19 is a  
10 multi-system disease resulting in the derangements of home-  
11 ostasis affecting pulmonary, cardiovascular, coagulation, haema-  
12 tological, oxygenation, hepatic, renal and fluid balance [2, 3, 4,  
13 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. Although the major-  
14 ity of people with COVID-19 will have mild or no symptoms,  
15 a small but significant proportion will suffer from a severe in-  
16 fection needing hospitalisation for supportive care, oxygen, or  
17

18 admission to intensive care units (ICU) for respiratory support.

19 Early identification of hospitalised COVID-19 patients who  
20 are likely to deteriorate, i.e. transfer to ICU or who may die,  
21 is vital for clinical decision making. Healthcare systems across  
22 the world including highly developed countries continue to face  
23 challenges in terms of capacity and resources to manage this  
24 pandemic, as lock down measures have been relaxed, including  
25 opening of schools and businesses.

26 To date, published prediction models have evaluated case-  
27 level factors that might predict poor outcomes (critical illness  
28 or death). A recent living systematic review [17] identified 265  
29 prognostic models for mortality and 84 for progression to se-  
30 vere or critical state. The majority of the studies looked at vital  
31 signs, age, comorbidities, and radiological features. Models  
32 were unlikely to include a broad range of variables concern-  
33 ing co-infection, biochemical factors (outside of C-reactive pro-  
34 tein), and other haematological factors on an individual patient  
35 level. Most of the prognostic models did not describe the target  
36 population or care setting adequately, did not fully describe the  
37 regression equation, showed high or unclear risk of bias and/or  
38 were inadequately evaluated for performance.

\*Dowsey and Albur are joint senior authors

\*\*Corresponding authors

Email address:

[brian.sullivan@bristol.ac.uk](mailto:brian.sullivan@bristol.ac.uk), [mahableshwar.albur@nbt.nhs.uk](mailto:mahableshwar.albur@nbt.nhs.uk)

(Mahableshwar Albur) **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

39 **Goals**

40 The present study analyzes a range of laboratory blood marker  
 41 values across metabolic pathways affected by COVID-19 infec-  
 42 tion (i.e. a core set of biomarkers feasible for clinical collec-  
 43 tion) and evaluates predictive models of severe outcomes. The  
 44 main objectives of the study are: (1) Examine statistical associa-  
 45 tions of routinely measured physiological and blood biomark-  
 46 ers, and age and gender, to predict severe COVID-19 outcomes.  
 47 (2) Develop cross-validated logistic regression prediction mod-  
 48 els using the candidate biomarkers, highlighting biomarkers wor-  
 49 thy of future research. (3) Use variable selection techniques in-  
 50 cluding least absolute shrinkage and selection operator (LASSO)  
 51 regularisation [18] and Bayesian Projective Prediction [19] to  
 52 illustrate the process of creating a reduced model that maintains  
 53 reasonable performance and is more feasible to use clinically.  
 54 (4) In each of these steps, demonstrate best analytic practices  
 55 for explaining clinical data curation and statistical modelling  
 56 decisions, with an emphasis on showcasing the capabilities of  
 57 recent Bayesian methods.

58 **Methods**

59 *Study Cohort and Demographics*

60 Pseudonymised data was obtained from Laboratory Informa-  
 61 tion Management Systems (LIMS) linking patient data for  
 62 laboratory markers to key clinical outcomes. Three hospitals in  
 63 the Southwest region of England, UK, participated in the study,  
 64 two of which were tertiary teaching hospitals and the third was  
 65 a district general hospital (DGH). A system-wide data search  
 66 was conducted on the LIMS for all patients who tested positive  
 67 for SARS-CoV-2 by polymerase chain reaction (PCR) at these  
 68 three hospitals during the first wave of COVID-19 pandemic  
 69 (01/03/2020 to 31/10/2020). The serial pathology data col-  
 70 lected as a part of standard of care of patients admitted with/  
 71 for COVID-19 were included- bacteriology, virology, mycology,  
 72 haematology, and biochemistry. All patients testing negative  
 73 for SARS CoV-2 by PCR were excluded. All laboratory mark-  
 74 ers including clinical outcomes from LIMS were extracted and  
 75 the final dataset was anonymized with no patient identifying  
 76 data to link back.

77 *Inclusion and exclusion criteria*

78 We included all adult patients admitted to study hospitals  
 79 and tested positive for SARS CoV-2 by PCR. Pediatric patients  
 80 (<18 years old) and staff/healthcare workers and their house-  
 81 hold contacts were excluded. Figure 1 depicts the decision  
 82 flow for inclusion and exclusion of patient data.

83 *Data Covariates*

84 The LabMarCS dataset includes a variety of host, clinical  
 85 severity indices, microbiological, immunological, haematolog-  
 86 ical and biochemistry parameters used as predictive variables  
 87 in the regression models. A full list of recorded data items is  
 88 shown in Figure 2




Figure 1: Flowchart of patient exclusion and inclusion criteria. The initial set of 1159 candidate patients was narrowed to a training set (n=590) and a validation set (n=253).

Biomarker	Abbreviation	Place Recorded / Reason	No. of Readings	% of Patients	Reference Range/ Criteria	Clinical Categories	Criteria Description
<b>Blood Clotting Tests</b>							
Activated partial thromboplastin time	APTT	Admission	422	50%	Normal between 21-33 seconds	Normal, Abnormal	Normal: <33; Mild: 33-49.5; Moderate: 49.5-82.5; Severe: >82.5
Prothrombin Time	PT	Admission	435	52%	Normal between 9.5-13 seconds	Normal, Abnormal	Abnormal: >=13
<b>Blood Gas Tests</b>							
Carbon Dioxide	CO2	Arterial/ Point of care	154	18%	Normal: 4.6-6.4 seconds	Normal, Abnormal	Abnormal if outside range
Lactate	pocLAC	Arterial/ Point of care	154	18%	0.5-2.2 mmol/L	Normal, Abnormal	Abnormal if <0.5 or >2.2
Oxygen	O2	Arterial/ Point of care	154	18%	11.0-14.4 seconds	Normal, Abnormal	Abnormal if <11 or >14.4
Bicarbonate Excess	BE	Arterial or Venous / Point of care	418	50%	22-29	Normal, Abnormal	Abnormal if outside range
pH acid/base scale	pH	Arterial or Venous / Point of care	417	49%	7.35-7.45	Normal, Abnormal	Abnormal if outside these bounds
<b>Coinfection Battery</b>							
Blood Culture	bc_coinfection	Admission	843	100%	34 bacterial strains tested	Positive, Negative	Positive if one or more positive
Respiratory	resp_coinfection	Admission	843	100%	34 bacterial strains tested	Positive, Negative	Positive if one or more positive
Urine	urine_coinfection	Admission	843	100%	34 bacterial strains tested	Positive, Negative	Positive if one or more positive
Viral	viral_coinfection	Admission	843	100%	10 viral infections tested	Positive, Negative	Positive if one or more positive
<b>Diabetes</b>							
Glucose	Glucose	Point of Care / Record Often Not Digitized	222	26%	Non-fasting: 3.0-7.8 mmol/L	Normal, Abnormal	Abnormal if outside range
<b>Full Blood Count Tests</b>							
Hemoglobin	HB	Admission	772	92%	Male 130-170 g/L, Female 120-150 g/L	Normal, Mild, Moderate, Severe	Normal: >gender specific criteria; Mild: 100 to gender specific criteria; Moderate: 80-100; Severe: <80
Platelet Count	PLT	Admission	770	91%	150-450 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal: >150; Mild: 100-150; Moderate: 50-100; Severe: <50
Lymphocytes	Lymphocyte	Admission	772	92%	1.5-4.5 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal 1.5-4.5; Mild 1-1.5; Moderate 0.5-1; Severe: <0.5 or >4.5
Neutrophils	Neutrophil	Admission	772	92%	2.0-7.5 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal 2-7.5; Mild 1-2; Moderate: 0.5-1; Severe: <0.5 or >7.5
Neutrophil - Lymphocyte Ratio	NLR	Admission	772	92%	0.78 and 3.53	Normal, Mild, Moderate, Severe	Normal: <3; Mild: 3-8; Moderate: 8-18; Severe: >18
White Cell Count	WCC	Admission	772	92%	4.0-11.0 10 <sup>9</sup> /L	Normal, Mild, Moderate, Severe	Normal: 4-11; Mild: 1-4; Moderate: 0.5-1; Severe: <0.5 and >11
<b>Urea &amp; Electrolytes Tests</b>							
C-Reactive Protein	CRP	Admission	759	90%	< 6 mg/L	Normal, Abnormal	Abnormal if greater than criteria
Estimated Glomerular	eGFR	Admission	707	84%	>90	Normal, Abnormal	Abnormal if greater than criteria
Urea	urea	Admission	754	89%	2.5-7 10 <sup>9</sup> /L	Normal, Abnormal	Abnormal if outside these bounds
<b>Investigatory Tests</b>							
Brain / B-type natriuretic peptide	BNP	Cardiac Function	47	6%	Men under 70: <100pg/ml, Women under 70: <150 pg/ml, All 70yr and over: <300 pg/ml	Normal, Abnormal	Abnormal if greater than age/gender specific criteria
D-Dimer	DDM		111	13%	Age (Years) D-dimer (ng/ml) <60 <500 61-70 <600 71-80 <700 81-90 <800 >90 <900	Normal, Abnormal	Abnormal if greater than age-specific criteria
Ferritin	FER		115	14%	Male: 33-490, Female(0-44): 15-445, Female(45+yr): 30-470	Normal, Mild, Moderate, Severe	Normal: <age/gender appropriate criteria; Mild: >criteria-735; Moderate: 735-2450; Severe: >2450
Fibrinogen	fib		104	12%	1.8-4.0 g/L	Normal, Mild, Severe.	Normal: >1.8; Mild: 1-1.8; Severe: <1
Glycated haemoglobin	HBA1c	Diabetes	17	2%	>=48 mmol/mol	Normal, Abnormal	Abnormal if greater than criteria
Lactate dehydrogenase	LDH	Investigatory	66	8%	240-480 IU/L	Normal, Mild, Moderate, Severe	Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440
Procalcitonin	PCT	ITU / Bacterial Infection	39	5%	Normal range: <0.2ng/mL	Normal, Abnormal	Abnormal: >=0.2
Triglycerides	trig	Investigatory	19	2%	0.5-1.7 mmol/L	Normal, Abnormal	Abnormal if outside these bounds
Troponin-T	trop	Cardiac Function	177	21%	Normal: <14ng/L	Normal, Abnormal	Abnormal if greater than criteria
<b>Covid-19 Test</b>							
Covid CT	Covid CT		843	100%	Threshold unique to type of test. Lab reports categorical 'positive' variable alongside CT value	Positive, Negative	Only positives included in current study
<b>Other Data</b>							
Age	Age		843	100%		Continuous	All ages >=18
Gender	Gender		843	100%		Male, Female	
Covid Positive on Admission	OnAdmission		843	100%		True, False	Tested only in univariate evaluation
Outcome	Outcome		843	100%		Discharge, ICU, Death	

Figure 2: Variables recorded in the LabMarCS dataset, including plain text description, abbreviation, place of record, frequency in the dataset, and criteria used for converting continuous readings into categorical values.




Figure 3: Example a single patient’s time series laboratory biomarker data. See Figure 2 for biomarker abbreviations. Biomarker results are normalised to span 0 to 1 via offsetting by the absolute value of the minimum value and dividing by the maximum value.




Figure 4: Example distribution of biomarker readings for Neutrophil Training and Validation Data. Vertical lines indicate clinical thresholds for bounds on Normal, Mild, Moderate, and Severe categorization.

## 89 Outcomes

90 For all sites, the primary prediction outcome was death or  
 91 transfer to the ICU within 28 days of the critical date. This  
 92 critical date was either the point of admission to hospital, or  
 93 the date of the first positive COVID-19 PCR test result if the  
 94 patient was already admitted. This generally corresponds to  
 95 WHO-COVID-19 Outcomes Scale Score 6–10 (severe) versus  
 96 0–5 (mild/moderate) [20].

## 97 Patient Timelines

98 The collected laboratory biomarkers are continuous mea-  
 99 sures and provide a time-series representation of the course of a  
 100 patient’s admission. Figure 3 shows an example of a single pa-  
 101 tient’s readings over the course of 18 days between testing posi-  
 102 tive for COVID-19 and being released from hospital care. This  
 103 provides a representative example of the heterogeneity seen in  
 104 our dataset, i.e. not all tests are taken and others are taken regu-  
 105 larly or intermittently (further examples in Supplementary Fig-  
 106 ures S2 - S6).

## 107 Transformation of Biomarker Data

108 Prediction modelling of irregularly sampled time-series data,  
 109 is a challenging open research question [21]. In this study we  
 110 focused on established and available tools for conventional and  
 111 Bayesian prediction. To balance inclusion of test data not avail-  
 112 able on the day of admission and the need for clinical decisions  
 113 to be guided soon after admission, we chose to consider the first  
 114 value recorded for each biomarker within three days of their  
 115 ‘critical date’. We additionally considered the worst or best  
 116 readings within 1, 5 or 7 days, but found the first reading within  
 117 3 days to be the most realistic compromise. In addition, we  
 118 transformed continuous biomarkers into categorical variables  
 119 via reference ranges for clinical use in the typical healthy popu-  
 120 lation ranges, see Figure 2. As an example, Figure 4 shows the  
 121 histogram of readings for all values recorded for Neutrophils,  
 122 including clinical thresholds to transform into categorical data.  
 123 No missing data imputation was performed, instead missing-  
 124 ness was coded as as an additional category ‘Test not taken’.

125 For further elaboration these modelling choices and the chal-  
 126 lenges, please see Discussion section.

## Statistical Analysis

Analytics were carried out using the R statistical language  
 (v4.13) and R Studio (Prairie Trillium release). We used the  
 following packages: Standard logistic regression analyses used  
 the R Stats GLM package (v3.6.2); LASSO analyses, GLMnet  
 (v4.1-4); and for Bayesian analyses, BRMS (v2.17) and Pro-  
 jPred (v2.1.2). Source code for this analysis pipeline can be  
 found at <https://github.com/biospi/LABMARCS>.

## Analysis of Individual Biomarkers

Before running full regression models, we examined the  
 independent contribution of individual biomarkers in predict-  
 ing ICU entry or death via standard logistic regressions and  
 Bayesian logistic regressions with either a flat (aka uniform) or  
 horseshoe prior. This allowed calculation of p-values and odds  
 ratios for each biomarker. A 5-fold cross-validation repeated  
 20 times was run for each biomarker to estimate median AUC  
 and 95% interquartile intervals. Stratified cross-validation data  
 shuffling was precomputed so all models used the same starting  
 data. Stratified cross-validation separates patients by outcome  
 (two groups of patients with severe outcomes and those with-  
 out), and shuffles both into 5 groups (yielding an 80/20 train-  
 ing/test for each fold). These groups are combined ensuring all  
 training and test datasets reflect the actual portion of patients  
 with severe outcomes for that particular biomarker and not a  
 random sample of that portion, which helps guarantee model  
 convergence for biomarkers with high data missingness.

Only complete cases of training data available for each biomarker  
 were considered, i.e. we did not include data for variables  
 marked ‘Test not taken’, to focus on the predictive power of test  
 results. Each individual biomarker model included age and gen-  
 der (except univariate age and gender models) and were com-  
 pared against a standard model including only age and gender.  
 Regressions were fit using all associated dummy variables for a



160 given biomarker (e.g. 'Mild', 'Moderate', 'Severe') using 'Normal' as the reference.

### 162 *Analysis Using All Valid Biomarker Data*

163 After individual biomarker evaluation, logistic regression models considering all valid biomarkers (Prediction Using Individual Variables section) and demographic variables were fit to the data. Their predictions were tested via internal and external validation using the stratified cross-validation procedures detailed above, expect models were fit using all available training data using 'Test Not Taken' for absent data. The models include a standard logistic regression, a logistic regression regularised with LASSO, and two Bayesian models using a flat and a horseshoe prior [22]. LASSO encourages models to converge on sparse solutions with most coefficients set to zero to achieve variable reduction as discussed in the Reduced Variable Models section. Bayesian horseshoe prior models similarly encourage sparse solutions but without making hard decisions on variable inclusion - this can subsequently be performed using Projective Prediction.

### 179 *Analysis Using Reduced Variable Models*

180 While a model using all biomarker data may have strong predictive power, it is clinically desirable to have a strong prediction with the least amount of biomarkers possible to save on resources devoted to biomarker collection. We used two methodologies to choose reduced variable models to predict COVID-19 severe outcomes, LASSO and Bayesian Projective Prediction.

187 LASSO is an optimization constraint that shrinks parameters according to their variance, reduces over-fitting, and enables variable selection [18]. The optimal degree of regularisation is determined by tuning parameter  $\lambda$  within each cross-validation fold through a nested cross-validation step. LASSO has a drawback of having biased coefficient and log-odds estimates, as such after evaluating LASSO models we run a standard GLM model on the reduced biomarker panel selected with the LASSO.

196 To evaluate LASSO coefficient estimates, we performed repeated nested stratified cross-validation (5-folds for the inner LASSO loop; 5-folds for the outer loop, and 20 repeats). For a particular dataset fit, LASSO optimises for a sparse representation with many coefficients set to zero. Across cross-validated trials these variables will vary. LASSO fits are statistically biased and are better suited as a guide for variable selection in a reduced variable standard GLM. As recommended in Heinze et al [23], we consider the frequency of how often a particular biomarker has a coefficient greater than zero and count across cross-validation trials.

207 For determining unbiased effect sizes for the reduced variable set with a standard GLM, it was chosen that if at least one categorical level for a particular biomarker (e.g. 'Severe') was selected by the LASSO, all levels for that biomarker were included in the model. This resulted in a final set of 'LASSO inspired' variables that were then fit with standard logistic GLM. Note this approach, and more generally fitting multiple models

to the same dataset, is subject to the problem of selective inference (aka multiple comparison error), see [24, 25] and the related R package [26]. Given our focus is not on reporting p-values, but instead cross-validation and generalisation from training data to validation data, these concerns are minimized.

The second variable selection method explored was Bayesian Projective Prediction [19], a technique for assessing reduced variable models against a complete 'reference' model, which in our case is a Bayesian logistic regression with a horseshoe prior [22]. Priors such as the horseshoe can be applied to provide adaptive shrinkage to covariates in Bayesian models directly so that full posterior distributions of odds estimates can be generated in an unbiased way. Unlike the LASSO, this does not shrink coefficients to zero exactly as the inherent uncertainty is not ignored. To perform hard variable selection, the recent approach of Projective Prediction can be used to compare the fit of submodels of the reference model through projections and approximate leave-one-out (LOO) cross-validation. Under the hood, Projective Prediction uses LASSO (or forward search) to select submodels for comparison, but retains the Bayesian inference for coefficient ranking and odds-ratio estimates. This approach allows one to evaluate the trade-off between AUC performance and the number of variables included in the model and use a reduced model projection at a desired AUC cutoff. Further projective prediction allows the flexibility to train one model on all valid available data, perform variable selection, and then use any projected sub-model with reduced variables to predict outcomes for novel data. Projective prediction models were evaluated using cross-validation procedures described in prior sections. Note, the analysis of the projective prediction model using all training data uses LOO for variable selection, which is computationally intensive. To speed variable selection computation during our cross-validation analysis, we used 'naive' variable selection, which only considers the training data from current fold as is, and does not perform any further internal cross-validation (the projective prediction package allows naive, k-fold, and LOO).

## 213 **Results**

### 214 *Cohort Description*

215 The initial cohort included 1159 patients which was narrowed down to 843 patients who met all inclusion criteria described above, see Figure 1. 57% of patients were hospitalised for COVID-19 and the remainder had nosocomial infection. For our statistical models, the training cohort (n=590) was defined as all adults admitted to hospital and testing positive for SARS-Cov-2 by PCR, or testing positive while already admitted between March and October 2020. For external validation, we held the DGH cohort (n=253) out of training. Figure 5 depicts the distribution of ages and genders in the training and validation data sets. Patients in the training set had a mean age of 70, were 44% female, and 29% had severe outcomes. The validation set had a mean age of 75, were 47% female, and 38% had a severe outcome.




Figure 5: Distribution of age and gender for hospitalized patients with coronavirus disease 2019 (COVID-19) for (Top) training data (n=590) and (Bottom) hold out validation data (n=253) cohorts.

### Regression Models Using All Valid Biomarker Data

Each model was evaluated via 5-fold stratified cross-validation with 20 repeats (100 models total). As such, each model is trained with a randomised sample of 80% of the training data set (n=472). Internal validation evaluates model predictions on the 20% (n=118) held out. External validation uses the same model, but is instead tested on the never trained on validation data set (n=253). Missing data for each biomarker is coded as 'Test Not Taken' and is included as a predictor variable. Figure 8 shows the performance of these models (AUC, Sensitivity, Specificity). For comparison, Figure 9 shows the performance of each model using all valid training data (n=590) and testing on the same data (internal validation) and testing on the held out external validation data (n=253).

Models trained on the full data have improved AUC scores, but do not provide a direct uncertainty estimate. For a single model this could be done via bootstrapping, but would not include uncertainty in model fit. Instead we compute inter-quantile ranges using 5-fold 20-repeat cross-validation of models. Cross-validation results provide 95% inter-quantile ranges that clearly illustrate that in general, all models perform similarly, with a median AUC in the mid 0.70's in internal validation, and near the high 0.60's in external validation. The Bayes model with horseshoe prior slightly outperforms all others, as shown in the AUC difference column showing the distribution of pair-wise differences across folds and repeats. The calibration of the models is reasonably good on the full data, all training data, but has poor calibration on the validation set, see Supplementary Figure S9.

### Prediction Using Individual Variables

Figure 6 shows descriptive statistics on individual biomarker readings and their odds ratio contributions in a 5-fold 20-repeat stratified cross-validated logistic regression including the particular biomarker and age and gender. Figure 7 details performance using the area under the receiver operating characteristic curve (AUC) metric, comparing biomarker models (a particular biomarker plus age and gender) to a model using only age and gender. Due to the categorical representation of the biomarkers, individual levels may be significant while another is not (e.g. 'Severe' is a predictor, but 'Mild' is not). Statistically significant predictors (i.e. odds ratios deviating from one with p-value at 0.05 or lower) associated with increasing risk of a severe outcome (as shown in Figure 6) include age, and the biomarkers: Activated Partial Thromboplastin Time (Mild), Prothrombin time (Abnormal), blood pH (Abnormal), Haemoglobin (Severe), Platelet count (Moderate), Lymphocytes (Moderate, Severe), Neutrophils (Severe), Neutrophil-Lymphocyte Ratio (Mild, Moderate, Severe), C-Reactive Protein (Abnormal), Urea (Abnormal), and Troponin-T (Abnormal). Nosocomial transmission was included due to the high number of cases in our cohort but was not a significant predictor and excluded from further analyses. Due to small numbers preventing cross validation, Triglycerides, Glycated Haemoglobin, and Procalcitonin (also invalid due to being recorded only in ICU) were excluded from further analysis and require future research.

### Reduced Variable Models

The models detailed above are moderately good predictors of severe COVID-19 outcomes, but for clinicians with limited time and resources, reduced models can balance predictive performance with ease of clinical use by using only the most informative biomarkers. To address this, we use two variable selection approaches, LASSO and projective prediction, that allow the creation of reduced models with fewer biomarkers but similar performance to the larger models.

### LASSO Models

After performing 5-fold 20 repeat cross-validation we examined the frequency of how often a particular biomarker has a coefficient greater than zero and count across cross-validation trials. Figure S10 shows the frequency of variables having a coefficient great than zero in the cross-validated LASSO analysis. If we select variables that appear at least 50% of the time, our reduced model would include: Age, CRP (abnormal), FER (mild), FIB (mild), HB (severe), PLT (mild, moderate, severe), Lymphocytes (Severe), Neutrophils (Mild, Severe), NLR (Severe), APTT (mild, moderate), PT (abnormal), blood pH (abnormal), Urea (abnormal), and positive viral and blood culture co-infections.

For the reduced variable standard GLM, this resulted in a model using the 15 biomarkers above for all categorical levels, and was evaluated via both cross-validation and as fit to all

Biomarker	Binary Categorical Variable	% of Patients with Biomarker Recording	# TRUE (% of TRUE Observations with Severe Outcome)	# FALSE (% of FALSE Observations with Severe Outcome)	Standard Logistic GLM		Bayesian Logistic (Flat Prior)	Bayesian Logistic (Horse Shoe Prior)
					P Value	Odds Ratio [2.5%, 97.5%]	Odds Ratio [2.5%, 97.5%]	Odds Ratio [2.5%, 97.5%]
<b>Demographics / Other</b>								
Age	-	100%	-	-	3.22E-05	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]
Gender	Female	100%	257 (26%)	333 (32%)	0.08	0.72 [0.50, 1.03]	0.72 [0.50, 1.03]	0.79 [0.54, 1.07]
Age & Gender	-	100%	-	-	2.83E-05	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]
	Female		257 (26%)	333 (32%)	0.06	0.70 [0.49, 1.02]	0.70 [0.48, 1.02]	0.83 [0.55, 1.07]
Nosocomial Transmission	TRUE	100%	240 (30%)	350 (29%)	0.65	0.92 [0.63, 1.33]	0.91 [0.63, 1.32]	0.94 [0.70, 1.21]
<b>Blood Clotting Tests</b>								
Activated partial thromboplastin time	Mild	54%	30 (63%)	291 (320%)	2.44E-03	3.44 [1.57, 7.88]	3.6 [1.52, 8.30]	2.79 [1.12, 6.19]
	Moderate	54%	4 (100%)	317 (34%)	0.98	9.91E+06 [0.00, NA]	5.3E+106 [7.9E+05, Inf]	6.84 [0.92, 218.16]
Prothrombin Time	Abnormal	56%	45 (58%)	288 (31%)	2.96E-03	2.73 [1.41, 5.36]	2.18 [1.01, 4.67]	2.26 [1.01, 4.63]
<b>Blood Gas Tests</b>								
Carbon Dioxide	Abnormal	21%	68 (59%)	57 (51%)	0.33	1.44 [0.70, 2.99]	1.46 [0.69, 3.01]	1.08 [0.82, 1.92]
Lactate	Abnormal	21%	13 (54%)	112 (55%)	0.96	1.03 [0.32, 3.44]	1.03 [0.32, 3.50]	1.00 [0.58, 1.64]
Oxygen	Abnormal	21%	105 (55%)	20 (55%)	0.98	1.01 [0.38, 2.66]	1.01 [0.37, 2.69]	1.00 [0.65, 1.54]
Bicarbonate Excess	Abnormal	64%	123 (38%)	252 (31%)	0.26	1.30 [0.82, 2.05]	1.30 [0.82, 2.00]	1.11 [0.86, 1.70]
pH acid/base scale	Abnormal	63%	136 (46%)	238 (26%)	1.05E-04	2.45 [1.56, 3.87]	2.48 [1.59, 3.96]	2.23 [1.33, 3.57]
<b>Coinfection</b>								
Blood Culture	TRUE	100%	5 (0%)	585 (30%)	0.98	3.20E-07 [NA, 2.94E+22]	2.17E-140 [0, 2E-05]	0.45 [0.01, 1.26]
Respiratory	TRUE	100%	6 (50%)	584 (29%)	0.20	2.95 [0.52, 16.62]	2.94 [0.48, 18.21]	1.30 [0.69, 5.62]
Urine	TRUE	100%	12 (25%)	579 (30%)	0.63	0.72 [0.15, 2.53]	0.64 [0.14, 2.46]	0.93 [0.36, 1.56]
Viral	TRUE	100%	7 (71%)	583 (29%)	0.06	4.95 [1.04, 35.13]	5.86 [1.06, 44.82]	1.92 [0.82, 12.53]
<b>Diabetes</b>								
Glucose	Abnormal	30%	49 (45%)	126 (32%)	0.11	1.77 [0.88, 3.54]	1.80 [0.90, 3.63]	1.31 [0.85, 2.60]
<b>Full Blood Count Tests</b>								
Hemoglobin	Mild	92%	176 (36%)	368 (27%)	0.13	1.38 [0.91, 2.08]	1.37 [0.91, 2.08]	1.14 [0.90, 1.74]
	Moderate		48 (33%)	495 (30%)	0.62	1.19 [0.59, 2.29]	1.17 [0.59, 2.31]	1.02 [0.68, 1.57]
	Severe		11 (55%)	532 (30%)	0.03	4.08 [1.16, 15.06]	4.22 [1.20, 15.15]	1.63 [0.83, 7.16]
Platelet Count	Mild	92%	67 (39%)	474 (29%)	0.07	1.65 [0.95, 2.83]	1.65 [0.93, 2.86]	1.33 [0.90, 2.31]
	Moderate		17 (65%)	524 (29%)	0.01	4.21 [1.54, 12.65]	4.40 [1.53, 13.35]	2.58 [0.97, 8.33]
	Severe		4 (75%)	537 (30%)	0.12	6.16 [0.76, 126.83]	9.34 [0.84, 305.58]	1.86 [0.69, 17.37]
Lymphocytes	Mild	92%	151 (27%)	392 (31%)	0.12	1.69 [0.89, 3.34]	1.71 [0.89, 3.26]	1.06 [0.73, 1.86]
	Moderate		217 (31%)	326 (30%)	0.03	1.96 [1.07, 3.75]	1.99 [1.08, 3.70]	1.21 [0.88, 2.18]
	Severe		84 (48%)	459 (27%)	4.99E-04	3.48 [1.75, 7.17]	3.53 [1.74, 7.11]	2.00 [1.00, 4.35]
Neutrophils	Mild	92%	23 (13%)	520 (31%)	0.23	0.47 [0.11, 1.43]	0.41 [0.09, 1.34]	0.71 [0.22, 1.29]
	Moderate		3 (33%)	540 (30%)	0.67	1.71 [0.08, 19.15]	1.29 [0.04, 21.86]	1.07 [0.30, 3.80]
	Severe		143 (41%)	400 (26%)	1.88E-03	1.92 [1.27, 2.91]	1.93 [1.28, 2.92]	1.75 [1.07, 2.70]
Neutrophil - Lymphocyte Ratio	Mild	92%	237 (28%)	306 (32%)	3.69E-03	2.50 [1.38, 4.79]	2.60 [1.40, 5.05]	1.83 [0.99, 3.58]
	Moderate		137 (39%)	406 (27%)	3.18E-05	3.97 [2.12, 7.81]	4.13 [2.19, 8.23]	2.90 [1.42, 5.80]
	Severe		54 (54%)	489 (28%)	2.61E-06	6.38 [2.99, 14.14]	6.72 [3.06, 15.22]	4.48 [1.91, 10.15]
White Cell Count	Mild	92%	57 (23%)	486 (31%)	0.34	0.72 [0.36, 1.38]	0.70 [0.35, 1.32]	0.84 [0.47, 1.23]
	Moderate		2 (50%)	541 (30%)	0.45	3.03 [0.11, 83.24]	3.11 [0.08, 117.32]	1.15 [0.43, 5.00]
	Severe		85 (42%)	458 (28%)	0.02	1.84 [1.12, 3.00]	1.83 [1.10, 3.00]	1.48 [0.97, 2.68]
<b>Urea &amp; Electrolytes Tests</b>								
C-Reactive Protein	Abnormal	91%	489 (33%)	47 (4%)	1.49E-03	10.23 [3.08, 63.44]	13.12 [3.48, 77.20]	7.81 [2.44, 31.55]
Estimated Glomerular Filtration Rate	Abnormal	82%	350 (38%)	131 (18%)	0.06	1.76 [0.98, 3.23]	1.79 [0.98, 3.28]	1.42 [0.93, 2.83]
Urea	Abnormal	89%	262 (47%)	264 (15%)	4.23E-11	4.27 [2.79, 6.63]	4.33 [2.85, 6.79]	4.13 [2.69, 6.33]
<b>Investigatory Tests</b>								
Brain / B-type natriuretic peptide	Abnormal	7%	30 (53%)	14 (29%)	0.13	3.91 [0.73, 27.00]	4.78 [0.76, 34.31]	1.52 [0.74, 9.03]
D-Dimer	Abnormal	12%	52 (42%)	18 (33%)	0.67	1.29 [0.40, 4.43]	1.34 [0.40, 4.88]	1.11 [0.61, 2.62]
Ferritin	Mild	14%	11 (64%)	72 (39%)	0.09	3.61 [0.84, 17.70]	4.00 [0.85, 19.54]	1.30 [0.78, 5.08]
	Moderate	14%	28 (46%)	55 (40%)	0.27	1.79 [0.64, 5.15]	1.85 [0.66, 5.30]	1.09 [0.74, 2.36]
	Severe	14%	6 (33%)	77 (43%)	0.94	0.93 [0.11, 5.90]	0.82 [0.09, 5.71]	0.95 [0.35, 1.89]
Fibrinogen	Mild	5%	4 (75%)	26 (46%)	0.10	11.27 [0.85, 360.85]	24.77 [1.06, 1.29E+03]	1.40 [0.67, 11.84]
	Severe	5%	3 (67%)	27 (48%)	0.40	3.41 [0.23, 105.85]	3.41 [0.23, 105.85]	1.15 [0.46, 5.30]
Glycated haemoglobin*	Abnormal	3%	11 (9%)	4 (0%)	1.00	2.98E+08 [0, NA]	8.30E+11 [0.22, 4E+46]	1.28 [0.32, 15.50]
Lactate dehydrogenase	Mild	6%	12 (67%)	25 (56%)	0.49	2.61 [0.19, 71.00]	3.67 [0.18, 166.51]	1.14 [0.58, 3.98]
	Moderate	6%	16 (63%)	21 (57%)	0.78	1.81 [0.09, 77.89]	1.81 [0.09, 77.89]	1.01 [0.39, 2.45]
	Severe	6%	5 (60%)	32 (59%)	0.34	4.63 [0.22, 178.20]	7.51 [0.19, 465.95]	1.06 [0.43, 3.67]
Procalcitonin*	Abnormal	4%	21 (86%)	4 (100%)	1.00	1.15E-07 [NA, 1.6E+184]	2.3E-07 [1.05E-31, 5.16]	0.80 [0.08, 2.72]
Triglycerides*	Abnormal	3%	10 (90%)	5 (100%)	1.00	1.68E-09 [NA, Inf]	4.3E-07 [1.98E-30, 1.31]	0.74 [0.04, 3.05]
Troponin-T	Abnormal	24%	91 (44%)	51 (22%)	0.03	2.96 [1.17, 7.96]	3.07 [1.25, 7.91]	1.71 [0.91, 5.40]

\* Biomarkers not included in subsequent models due to small sample size, and recorded only in ICU (PCT)

Figure 6: Individual biomarker evaluation including descriptive statistics and logistic regression model outcomes (Standard, Bayesian with flat prior, and Bayes with horseshoe prior), including age and gender (except univariate age and gender models). Regressions were fit using all associated dummy variables for a given biomarker (e.g. normal, mild, moderate, severe) and using only complete cases of training data, i.e. not using a variable for 'Test not taken.' Categorical variables use a reading of 'Normal' as a reference in the fitted model, except 'Male' used as the reference category for gender.

	Standard Logistic GLM		Bayesian Logistic (Flat Prior)		Bayesian Logistic (Horse Shoe Prior)	
	Cross-Validated 80/20 Split		Cross-Validated 80/20 Split		Cross-Validated 80/20 Split	
Demographic / Biomarker	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]
<b>Demographics / Other</b>						
Age	0.62 [0.52, 0.74]	0.00 [-0.10, 0.03]	0.61 [0.45, 0.74]	0.01 [-0.10, 0.06]	0.61 [0.51, 0.73]	0.00 [-0.13, 0.03]
Gender	0.54 [0.45, 0.62]	0.07 [-0.06, 0.17]	0.54 [0.46, 0.64]	0.08 [-0.08, 0.20]	0.54 [0.47, 0.62]	0.07 [-0.11, 0.17]
Age & Gender	0.62 [0.51, 0.71]	0.00, [0.00, 0.00]	0.62 [0.51, 0.73]	0.00, [-0.02, 0.01]	0.61 [0.52, 0.72]	0.00, [-0.02, 0.02]
Nosocomial Transmission	0.61 [0.47, 0.69]	0.00 [-0.05, 0.04]	0.61 [0.48, 0.69]	0.00 [-0.02, 0.04]	0.61 [0.43, 0.70]	0.00 [-0.11, 0.02]
<b>Blood Clotting Tests</b>						
Activated partial thromboplastin time	0.65 [0.46, 0.78]	-0.04 [-0.23, 0.04]	0.65 [0.47, 0.78]	-0.04 [-0.24, 0.06]	0.64 [0.45, 0.77]	-0.04 [-0.15, 0.06]
Prothrombin Time	0.64 [0.46, 0.77]	-0.03 [-0.22, 0.06]	0.64 [0.47, 0.76]	-0.03 [-0.16, 0.05]	0.64 [0.50, 0.75]	-0.03 [-0.13, 0.04]
<b>Blood Gas Tests</b>						
Carbon Dioxide	0.54 [0.42, 0.69]	0.01 [-0.16, 0.24]	0.55 [0.42, 0.68]	0.00 [-0.15, 0.21]	0.56 [0.43, 0.69]	0.00 [-0.17, 0.13]
Lactate	0.57 [0.42, 0.72]	0.00 [-0.20, 0.10]	0.56 [0.40, 0.72]	-0.01 [-0.16, 0.19]	0.57 [0.42, 0.76]	0.00 [-0.23, 0.18]
Oxygen	0.57 [0.43, 0.74]	0.00 [-0.21, 0.14]	0.56 [0.42, 0.71]	0.00 [-0.16, 0.12]	0.54 [0.42, 0.70]	0.03 [-0.15, 0.18]
Bicarbonate Excess	0.57 [0.47, 0.70]	0.00 [-0.09, 0.11]	0.57 [0.45, 0.70]	0.00 [-0.08, 0.13]	0.58 [0.43, 0.72]	0.00 [-0.05, 0.13]
pH acid/base scale	0.65 [0.48, 0.75]	-0.07 [-0.18, 0.08]	0.65 [0.48, 0.74]	-0.07 [-0.26, 0.07]	0.64 [0.47, 0.75]	-0.06 [-0.21, 0.09]
<b>Coinfection</b>						
Blood Culture	0.62 [0.52, 0.71]	-0.01 [-0.02, 0.00]	0.62 [0.52, 0.72]	-0.01 [-0.03, 0.01]	0.62 [0.51, 0.72]	-0.00 [-0.13, 0.02]
Respiratory	0.61 [0.51, 0.73]	-0.00 [-0.02, 0.01]	0.62 [0.50, 0.73]	-0.00 [-0.05, 0.02]	0.62 [0.50, 0.73]	-0.00 [-0.02, 0.02]
Urine	0.61 [0.47, 0.70]	0.00 [-0.00, 0.04]	0.61 [0.48, 0.70]	0.00 [-0.03, 0.04]	0.62 [0.50, 0.71]	0.00 [-0.05, 0.02]
Viral	0.61 [0.48, 0.76]	-0.00 [-0.02, 0.01]	0.61 [0.47, 0.76]	-0.00 [-0.03, 0.02]	0.61 [0.46, 0.76]	-0.00 [-0.04, 0.03]
<b>Diabetes</b>						
Glucose	0.60 [0.44, 0.77]	-0.00 [-0.09, 0.15]	0.60 [0.45, 0.76]	-0.01 [-0.11, 0.17]	0.58 [0.46, 0.74]	-0.01 [-0.10, 0.19]
<b>Full Blood Count Tests</b>						
Hemoglobin	0.61 [0.52, 0.72]	-0.00 [-0.06, 0.07]	0.61 [0.53, 0.72]	-0.00 [-0.06, 0.08]	0.61 [0.51, 0.71]	-0.00 [-0.03, 0.05]
Platelet Count	0.63 [0.51, 0.74]	-0.01 [-0.07, 0.04]	0.63 [0.51, 0.73]	-0.01 [-0.07, 0.03]	0.63 [0.51, 0.73]	-0.01 [-0.09, 0.04]
Lymphocytes	0.65 [0.56, 0.76]	-0.03 [-0.10, 0.03]	0.65 [0.56, 0.76]	-0.04 [-0.17, 0.04]	0.63 [0.53, 0.73]	-0.02 [-0.08, 0.03]
Neutrophils	0.63 [0.53, 0.74]	-0.02 [-0.09, 0.06]	0.63 [0.53, 0.75]	-0.02 [-0.07, 0.06]	0.64 [0.54, 0.74]	-0.02 [-0.07, 0.04]
Neutrophil - Lymphocyte Ratio	0.67 [0.59, 0.75]	-0.05 [-0.15, 0.04]	0.67 [0.59, 0.75]	-0.05 [-0.14, 0.05]	0.67 [0.58, 0.74]	-0.05 [-0.16, 0.05]
White Cell Count	0.62 [0.50, 0.70]	-0.01 [-0.08, 0.07]	0.62 [0.49, 0.71]	-0.01 [-0.06, 0.08]	0.63 [0.49, 0.71]	-0.00 [-0.10, 0.06]
<b>Urea &amp; Electrolytes Tests</b>						
C-Reactive Protein	0.66 [0.54, 0.74]	-0.04 [-0.11, 0.01]	0.66 [0.55, 0.74]	-0.03 [-0.10, 0.02]	0.66 [0.55, 0.74]	-0.04 [-0.12, 0.01]
Estimated Glomerular Filtration Rate	0.62 [0.48, 0.74]	-0.01 [-0.03, 0.04]	0.63 [0.47, 0.74]	-0.00 [-0.03, 0.05]	0.62 [0.44, 0.74]	0.00 [-0.03, 0.03]
Urea	0.71 [0.60, 0.81]	-0.09 [-0.19, -0.01]	0.71 [0.60, 0.80]	-0.09 [-0.20, -0.01]	0.70 [0.60, 0.81]	-0.09 [-0.19, -0.00]
<b>Investigatory Tests</b>						
Brain / B-type natriuretic peptide	0.65 [0.38, 0.95]	-0.05 [-0.38, 0.25]	0.65 [0.40, 1.00]	-0.03 [-0.45, 0.25]	0.65 [0.40, 0.90]	0.00 [-0.40, 0.25]
D-Dimer	0.65 [0.44, 0.86]	0.01 [-0.11, 0.18]	0.65 [0.42, 0.90]	0.00 [-0.13, 0.18]	0.65 [0.40, 0.85]	0.00 [-0.17, 0.14]
Ferritin	0.60 [0.41, 0.81]	-0.01 [-0.24, 0.23]	0.60 [0.44, 0.83]	-0.01 [-0.30, 0.19]	0.59 [0.41, 0.79]	0.00 [-0.25, 0.21]
Fibrinogen	0.67 [0.44, 1.00]	0.00 [-0.44, 0.33]	0.67 [0.44, 1.00]	0.00 [-0.44, 0.33]	0.67 [0.44, 1.00]	0.00 [-0.44, 0.33]
Glycated haemoglobin*	NA	NA	NA	NA	NA	NA
Lactate dehydrogenase	0.67 [0.42, 1.00]	0.00 [-0.25, 0.33]	0.67 [0.42, 1.00]	0.00 [-0.27, 0.33]	0.67 [0.40, 1.00]	0.00 [-0.33, 0.27]
Procalcitonin*	NA	NA	NA	NA	NA	NA
Triglycerides*	NA	NA	NA	NA	NA	NA
Troponin-T	0.54 [0.39, 0.72]	0.01 [-0.23, 0.21]	0.56 [0.44, 0.72]	-0.00 [-0.23, 0.19]	0.57 [0.44, 0.74]	0.01 [-0.24, 0.16]

\* Biomarkers not included in subsequent models due to small sample size, and recorded only in ICU (PCT)

Figure 7: Predictive performance of the individual biomarker models in Figure 6 as described by the median area under the curve (AUC) in receiver operating curve (ROC) analysis and median difference between an Age and Gender reference model and the same model (negative values indicate the reference has worse performance) with the particular biomarker included (except univariate age and gender models). Regressions were fit using all associated dummy variables for a given biomarker (e.g. mild, moderate, severe) and using only complete cases of training data (n=590), i.e. not using a variable for 'Test not taken.' 95% inter-quartile ranges calculated via 5-fold cross-validation with 20 repeats (100 models total). Categorical variables use a reading of 'Normal' as a reference in the fitted model, except 'Male' used as the reference category for gender.



Model	Internal Validation				External Validation			
	AUC [2.5%, 97.5%]	Specificity at 90% Sensitivity [2.5%, 97.5%]	Specificity at 95% Sensitivity [2.5%, 97.5%]	AUC Difference	AUC [2.5, 97.5]	Specificity at 90% Sensitivity [2.5%, 97.5%]	Specificity at 95% Sensitivity [2.5%, 97.5%]	AUC Difference
Standard Logistic GLM	0.74 [0.62, 0.83]	0.40 [0.02, 0.61]	0.14 [0.00, 0.48]	-0.04 [-0.14, 0.03]	0.68 [0.61, 0.71]	0.27 [0.18, 0.37]	0.13 [0.02, 0.23]	-0.02 [-0.07, 0.01]
GLM with LASSO regularisation	0.78 [0.70, 0.85]	0.47 [0.27, 0.63]	0.34 [0.04, 0.54]	-0.01 [-0.04, 0.02]	0.69 [0.66, 0.71]	0.32 [0.24, 0.38]	0.19 [0.14, 0.26]	-0.01 [-0.03, 0.00]
Bayesian GLM (Flat Prior)	0.74 [0.62, 0.83]	0.42 [0.01, 0.63]	0.23 [0.00, 0.52]	-0.04 [-0.14, 0.02]	0.67 [0.60, 0.70]	0.27 [0.16, 0.36]	0.13 [0.01, 0.22]	-0.03 [-0.08, 0.00]
Bayesian GLM (Horse Shoe Prior)	0.79 [0.71, 0.87]	0.49 [0.35, 0.68]	0.37 [0.10, 0.58]	Reference	0.70 [0.68, 0.71]	0.34 [0.29, 0.40]	0.23 [0.17, 0.28]	Reference
LASSO inspired GLM (15 biomarkers)	0.80 [0.73, 0.87]	0.51 [0.34, 0.66]	0.39 [0.01, 0.60]	0.01 [-0.04, 0.05]	0.67 [0.65, 0.69]	0.28 [0.22, 0.34]	0.16 [0.10, 0.20]	-0.03 [-0.04, -0.01]
Projective Prediction (28 Biomarkers)	0.78 [0.71, 0.87]	0.50 [0.29, 0.65]	0.36 [0.07, 0.56]	-0.01 [-0.02, 0.04]	0.70 [0.68, 0.71]	0.34 [0.28, 0.40]	0.23 [0.16, 0.28]	0 [-0.01, 0.01]
Projective Prediction (3 Biomarkers)	0.79 [0.78, 0.80]	0.50 [0.46, 0.53]	0.41 [0.34, 0.46]	0.00 [-0.07, 0.08]	0.67 [0.65, 0.69]	0.27 [0.23, 0.31]	0.19 [0.15, 0.24]	-0.03 [-0.05, -0.01]

Figure 8: Cross-validated performance of models trained using valid biomarker data. 95% inter-quantile ranges are presented for each estimate. Specificity is obtained by evaluating at a set sensitivity of either 90% or 95%. All reduced variable models include age, and a stated number of biomarkers. The reduced variable standard GLM uses 15 biomarkers that had non-zero coefficients on  $\geq 50\%$  LASSO Cross-validation trials. If at least one categorical level for a particular biomarker (e.g. severe) met this requirement, all levels for that biomarker were included in the model. The 3 biomarker projective prediction model uses all categorical levels for Urea, PT, and NLR. Pairwise AUC difference is presented in comparison to the Bayesian (Horse shoe prior) model.

Model	Internal Validation					External Validation				
	Accuracy	AUC	Brier	Sensitivity	Specificity	Accuracy	AUC	Brier	Sensitivity	Specificity
Standard Logistic GLM	0.82	0.87	0.13	0.93	0.56	0.66	0.69	0.13	0.82	0.40
Standard GLM with LASSO regularisation	0.77	0.83	0.23	0.94	0.39	0.62	0.69	0.38	0.93	0.13
LASSO inspired GLM (15 biomarkers)	0.79	0.84	0.14	0.91	0.50	0.67	0.69	0.14	0.88	0.34
Bayesian GLM (Flat Prior)	0.82	0.86	0.18	0.92	0.58	0.64	0.68	0.36	0.79	0.40
Bayesian GLM (Horse Shoe Prior)	0.79	0.84	0.21	0.94	0.45	0.63	0.71	0.37	0.89	0.22
Projective Prediction (28 Biomarkers)	0.79	0.83	0.21	0.94	0.44	0.64	0.71	0.36	0.90	0.24

Figure 9: Performance of models using all valid biomarker data trained on all training data available (n=590). Internal validation is trained on all of the training data and tested on the same. External validation uses the same model and is tested on held out validation data set (n=253). Missing data for each biomarker is coded as 'Test Not Taken'. Specificity and sensitivity evaluated using a probability threshold of 0.5 (i.e. assumes a well-calibrated model). All reduced variable models include age, and a stated number of biomarkers. The reduced variable standard GLM uses 15 biomarkers that had non-zero coefficients on  $\geq 50\%$  LASSO Cross-validation trials. If at least one categorical level for a particular biomarker (e.g. severe) met this requirement, all levels for that biomarker were included in the model. The 3 biomarker projective prediction model uses all categorical levels for Urea, PT, and NLR.

347 available training data. This model had performance very simi-373  
 348 lar to the models using all valid biomarker data, with a median374  
 349 external validation AUC of 0.68 [0.63, 0.72], see Figures 8 and375  
 350 9. 376

351 Note, 'Test Not Taken' is a significant predictor for LDH377  
 352 and Lactate on over 50% of cross-validation trials. The poten-378  
 353 tial significance of missing data is complex and is addressed in379  
 354 the Discussion section. Due to this confounding, biomarkers380  
 355 whose top predictive contribution was from 'Test Not Taken'381  
 356 were excluded from both LASSO reduced variable models and382  
 357 projective prediction models described below. 383

### 358 Projective Prediction Models 385

359 When all biomarkers were considered, projective prediction386  
 360 identifies the following predictors in the top 20, in order of con-387  
 361 tribution to AUC: Urea (abnormal), Age, PT (abnormal), NLR388  
 362 (Severe), pH (abnormal), Lymphocytes (severe), APPT(mild)389  
 363 eGFR (abnormal), Neutrophils (Severe), APPT(moderate), CRP390  
 364 (abnormal), DDM (abnormal), Hemoglobin (severe). Thus age391  
 365 and 12 biomarkers are candidates for a reduced model. Note392  
 366 several predictors of 'Test Not Taken' were also selected in-393  
 367 cluding Lactate, O2, CO2, LDH, Ferritin and Fibrinogen. As394  
 368 mentioned above, these biomarkers are set aside due to this395  
 369 confounding. Supplementary Figures S11 and S12 display396  
 370 the output from projective prediction ranking the contribution397  
 371 of each variable to the model. A model using a projection in-398  
 372 corporating all biomarker and demographic data is equivalent to399

the standard Bayesian GLM we evaluated in the prior section, see Figures 8 and 9.

Reduced variable projections were evaluated by manual inspection of AUC performance among groups of models using the top biomarkers. Guided by the projective prediction ranking, we ran a model using only the top biomarker, using only the top two, the top three, and so on. As described above we omit biomarkers with significant contributions from 'Test Not Taken' and include all categorical levels for a given biomarker as long as one level is highly ranked. Ultimately, we found a 3 biomarker projective prediction model using age and including urea, prothrombin time, neutrophil-lymphocyte ratios had similar performance to larger models with a median internal validation AUC of 0.79 [0.78, 0.80], and external validation AUC of 0.67 [0.65, 0.69], as shown in Figures 8 and 9. Odds ratios for the full Bayesian model and the reduced 3-biomarker model can be found in Supplementary Table S13. The calibration of the model is reasonably good on the training data but has poor calibration on the validation set, see Supplementary Figure S14.

## Discussion

### Challenges of Complex Medical Data

Curating the LabMarCS data is challenging as the data are heterogeneous in multiple ways. Biomarkers are recorded for

397 different reasons, e.g. routine upon admission, investigatory<sup>451</sup>  
398 tests, or tests primarily or exclusively taken in ICU. Further,<sup>452</sup>  
399 some biomarkers are typically recorded together (but not al-<sup>453</sup>  
400 ways) as part of a test suite, including: Urea and electrolytes,  
401 full blood count, COVID-19 and co-infection swab test, blood<sup>454</sup>  
402 clotting, and blood gas tests (arterial or venous). The schedule<sup>455</sup>  
403 when some these markers are recorded vary by patient and clin-<sup>456</sup>  
404 ical decision, leading to records being present in highly varying<sup>457</sup>  
405 amounts, e.g. only 3% up to 100% of patients depending on the<sup>458</sup>  
406 particular biomarker, see Supplementary Figure S1. <sup>459</sup>

#### 407 *Modelling Choices* <sup>460</sup>

408 When constructing and evaluating models, there are many<sup>462</sup>  
409 choice points that should be explicitly highlighted with justifi-<sup>463</sup>  
410 cation, be it based on convenience, computational complexity,<sup>464</sup>  
411 clinical advice, or a heuristic. The space of potential models<sup>465</sup>  
412 is vast and most studies will constrain the model search space,<sup>466</sup>  
413 delineating why these choices are made will facilitate under-<sup>467</sup>  
414 standing and reproduction by other researchers. These include<sup>468</sup>  
415 key choices relating to: patient inclusion/exclusion criteria, data<sup>469</sup>  
416 missingness protocols, data transformations, training and vali-<sup>470</sup>  
417 dation data selection, and performance evaluation. <sup>471</sup>

#### 418 *Missing Data* <sup>472</sup>

419 Missingness, in the context of this study and in healthcare<sup>474</sup>  
420 data more generally, can sometimes be informative and miss-<sup>475</sup>  
421 ing not at random (MNAR), with the presence or absence of a<sup>476</sup>  
422 test correlated with the its measurement or the study outcome.  
423 Imputation of missing data relies on key statistical assumptions<sup>477</sup>  
424 that imputed variables are missing at random (MAR) or missing<sup>478</sup>  
425 completely at random (MCAR). Conversations with our clini-<sup>479</sup>  
426 cal co-authors established some routinely collected biomark-<sup>480</sup>  
427 ers might be inferred to be MAR. However, the routines iden-<sup>481</sup>  
428 tified were specific to a small a subset of our cohort and not<sup>482</sup>  
429 likely to extrapolate. We ultimately erred to be conservative and<sup>483</sup>  
430 avoid all imputation, and instead include the presence/absence<sup>484</sup>  
431 of missing values as a covariate itself [27, 28]. As such, in the<sup>485</sup>  
432 current study we chose to use placeholders for 'Test not taken'<sup>486</sup>  
433 if there was no recorded value for a particular biomarker within<sup>487</sup>  
434 the evaluated 3-day window. <sup>488</sup>

435 This approach allows the possibility that a 'Test Not Taken'<sup>489</sup>  
436 may be a significant predictor. This has many potential mean-<sup>490</sup>  
437 ings, as it may convey that when a patient is doing well and<sup>491</sup>  
438 unlikely to experience a severe outcome, clinicians are unlikely<sup>492</sup>  
439 to request some biomarker tests. Alternatively, if a patient is in<sup>493</sup>  
440 palliative care and has a poor prognosis, a clinician may con-<sup>494</sup>  
441 sider further testing unnecessary. As such, the likelihood of a<sup>495</sup>  
442 test being administered may follow an inverted-U function as<sup>496</sup>  
443 patients to healthy or too ill may not have tests administered.<sup>497</sup>  
444 Furthermore, as our data was collected early in the pandemic,<sup>498</sup>  
445 there may be other underlying clinical decisions or resource<sup>499</sup>  
446 limitations that drove why some tests were taken but not others.<sup>500</sup>  
447 Lastly, because we only consider results from the first 3 day<sup>501</sup>  
448 from a patients critical date, it may be that some tests were sim-<sup>502</sup>  
449 ply taken later in a patient's stay due to operational constraints,<sup>503</sup>  
450 and hence may be more predictive as they were taken closer to<sup>504</sup>

the outcome. When these instances occurred, we were conser-  
vative and excluded biomarkers with 'Test Not Taken' as the  
most informative category from our reduced variable models.

#### *Data Transforms - Time Windows*

Ideally clinicians make decisions based on readings on the  
day of admission. However, not all tests are administered on  
admission. To balance inclusion of test data not available on  
the day of admission and the need for clinical decisions to be  
guided soon after admission, we chose to consider the first value  
recorded for each biomarkers within three days of their 'critical  
date', i.e. date of admission if already COVID-19 positive, or  
if already in hospital, the date of testing COVID-19 positive.  
However, given the richness of the time series data collected,  
further research into models that leverage this extra information  
is needed.

Focusing on early detection reflects the intent for the model  
to improve early stage clinical decision making when potential  
treatments or changes in care may be introduced. This focus  
on the first reading in a 3-day interval loses information, but  
greatly simplifies the modelling approach. Note, this choice is  
not without risk of reducing statistical power, increasing the risk  
of false positives, and underestimation of the extent of variation  
in biomarker readings and outcomes between groups [29]. It is  
likely that representing biomarker data as time-series (assum-  
ing regular measures across patients) would add considerable  
information for continuous monitoring.

#### *Data Transforms - Continuous vs. Categorical*

A key modelling decision must be made on whether to use  
continuous data or transformed categorical data. Clinicians of-  
ten use biomarker thresholds to provide semantic categories  
(e.g. normal, mild, moderate, severe) which sometimes use  
non-linear or discontinuous mappings that require special care  
if using continuous data. While clinical thresholds are likely  
established with evidence, it may be the case that thresholds  
for one use may not apply to a novel use. This led [30, 31] to  
use machine learning approaches to build categorisation models  
on continuous biomarker data dependent on the training data at  
hand. However, using machine learning to establish categorisa-  
tion thresholds on our biomarker data is difficult with a small  
training data set and the heterogeneity of biomarker recordings.  
If missing data imputation is performed, it raises another de-  
cision point on whether to impute the continuous or the trans-  
formed categorical data.

Another important factor to recognise is that some biomark-  
ers lack a linear relationship between a reading and a semantic  
category. Biomarkers can have a lower and upper bound for  
what is considered normal, and both below and above this range  
reflects clinically meaningful yet sometimes separate abnormal-  
ities. The modelling needs to factor in non-linearity when per-  
severing continuous data or trying to map to a categorical space.  
In our position, categorical transformation had an advantage, as  
they allowed us to collaborate with ICU consultants while using  
pre-established clinically acceptable ranges to define our cate-  
gorisation, see Figure 2.

## 505 *Training and Validation Data Selection*

506 There are multiple ways that our data set could be split be-  
507 tween training and validation sets, e.g. randomly sampling 1/3  
508 of the data to hold out as a validation set. Random selection  
509 of training data should in principle generate data more repre-  
510 sentative of the validation set left out. However, hospitals may  
511 have differing practices and non-stratified randomization may  
512 inflate performance at the cost of real world generalisation. We  
513 chose to separate our training and validation datasets by hospi-  
514 tal to provide a stronger test of generalisation that should mimic  
515 generalisation to novel hospitals completely outside the original  
516 training data .

## 517 *Model Performance Evaluation and Dissemination*

518 There are a variety of ways statistical model performance  
519 can be evaluated. Here we have chose here to emphasize cross-  
520 validated estimates of AUC, sensitivity, and specificity. Inter-  
521 quartile intervals over these measures reveal that the variety of  
522 models perform in similar ways. With a larger data set, trade-  
523 offs may become more apparent. Model calibration on the val-  
524 idation set is a clear weak point. While the models have a  
525 reasonable calibration for training data, generalisation perfor-  
526 mance is weak and suggestive of the lack of sufficient data.

## 527 *Comparison to Contemporary Models*

528 We found several biomarkers previously highlighted by other  
529 groups to have significant predictive power, including: Urea,  
530 Neutrophil-Lymphocyte Ratio, Lymphocytes, APTT, eGFR, and  
531 CRP. Our highly reduced 3-biomarker model (plus age) uses  
532 Urea (highlighted by all prior models), Neutrophil-Lymphocyte  
533 ratio (highlighted by [32, 11, 31]), and APPT (highlighted by  
534 [31]). With a larger dataset, further vetting of these and other  
535 biomarkers would be possible, but it gives reassurance that de-  
536 spite limitations, we find similar predictive biomarkers.

## 537 *Advantages of Bayesian Modelling*

538 While the predictive performance across models presented  
539 here is generally quite similar, the Bayesian horse shoe model  
540 had slightly better cross-validated predictive performance and  
541 there are several reasons for researchers to favor Bayesian ap-  
542 proaches. Coefficients estimated via Bayes should on average  
543 deliver better predictive performance than standard GLM. Ad-  
544 ditionally, if a sparse model is needed, a horseshoe prior can  
545 provide advantages similar to LASSO without biased coeffi-  
546 cient estimates. Computationally, Bayesian techniques can be  
547 slow due Markov Chain Monte Carlo used to sample the coeffi-  
548 cient space. If one is interested in variable selection, projective  
549 prediction offers the ability to take a single Bayesian model fit,  
550 run a variable selection algorithm to rank variable contributions,  
551 and then arbitrarily create sub-model projections with any num-  
552 ber of original variables. While the initial model fit and variable  
553 selection are computationally intensive, sub-model projections  
554 are fast to create and performance test.

## 555 **Summary & Conclusions**

*Limitations:* This is a retrospective cohort study in South-  
west England where case numbers have varied widely, and were  
below national incidence rates during the first wave. This re-  
sults in less precise parameter estimates for prediction models  
(less power/smaller sample size) and likely reduced generaliz-  
ability of the model to other settings. The timing of biomarker  
collection was highly varied both within and between patients,  
with many types of readings missing.

*Strengths:* The primary strength of our study is the granu-  
larity of serial laboratory data available linked to clinical out-  
comes. This study was performed during the first wave where  
there was the original Wuhan strain circulating amongst the un-  
vaccinated naïve population without any specific immunomod-  
ulating therapies such as steroids or antiviral agents, reflecting  
the “true” homeostasis derangements at a population level.

In particular, this study describes the variety of challenges  
present in complex medical data sets and how statistical best-  
practices can be applied to such data, highlighting the benefits  
of recent Bayesian methodology. Our study reiterates the pre-  
dictive value of previously identified biomarkers for COVID-  
19 severity assessment (e.g. age, urea, prothrombin time, and  
neutrophil-lymphocyte ratio). Both the full and reduced vari-  
able models have moderately good training performance, but  
improved external validation is needed for all models to be clin-  
ically viable. The methods presented here should generalise  
well to a larger dataset.

## 587 **Ethics approval**

The study [IRAS project ID: 283439] underwent a rigorous  
ethical and regulatory approval process, and a favourable opin-  
ion was gained from Research Ethics Service, Wales REC 7,  
c/o Public Health Wales, Building 1, Jobswell Road, St David’s  
Park, SA31 3HB on 11/09/2020.

## 588 **Funding**

This work is funded by Health Data Research UK via the  
Better Care Partnership Southwest (HDR CF0129), Medical  
Research Council Research Grant MR/T005408/1, the Elizabeth  
Blackwell Institute for Health Research, University of Bristol,  
and the Wellcome Trust Institutional Strategic Support Fund.

## 594 **Declaration of competing interest**

The authors have no competing interests.

## 598 **Acknowledgements**

This research was supported by the National Institute for  
Health and Care Research (NIHR) Applied Research Collab-  
oration West (NIHR ARC West). The views expressed in this  
article are those of the author(s) and not necessarily those of the  
NIHR or the Department of Health and Social Care.



## 602 References

- 603 [1] A. B. Docherty, E. M. Harrison, C. A. Green, H. Hardwick, R. Pius,  
604 L. Norman, K. A. Holden, J. M. Read, F. Dondelinger, G. Carson, L. Mer-  
605 son, J. Lee, D. Plotkin, L. Sigfrid, S. Halpin, C. Jackson, C. Gam-  
606 ble, P. W. Horby, J. S. Nguyen-Van-Tam, I. Investigators, J. Dunning,  
607 P. J. M. Openshaw, J. K. Baillie, M. G. Semple, Features of 16,749 hos-  
608 pitalised UK patients with COVID-19 using the ISARIC WHO Clinical  
609 Characterisation Protocol, medRxiv (2020) 2020.04.23.20076042doi:  
610 10.1101/2020.04.23.20076042. 682
- 611 [2] C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang,  
612 X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu,  
613 X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng,  
614 Y. Song, Risk Factors Associated With Acute Respiratory Distress Syn-  
615 drome and Death in Patients With Coronavirus Disease 2019 Pneumo-  
616 nia in Wuhan, China, JAMA internal medicine 180 (7) (2020) 934–943.  
617 doi:10.1001/jamainternmed.2020.0994. 688
- 618 [3] L. Bowles, S. Platton, N. Yartey, M. Dave, K. Lee, D. P. Hart, V. Mac-  
619 Donald, L. Green, S. Sivapalaratnam, K. J. Pasi, P. MacCallum, Lupus,  
620 Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-  
621 19, New England Journal of Medicine 383 (3) (2020) 288–290. doi:  
622 10.1056/NEJMc2013656. 694
- 623 [4] N. Tang, D. Li, X. Wang, Z. Sun, Abnormal coagulation parameters are  
624 associated with poor prognosis in patients with novel coronavirus pneu-  
625 monia, Journal of thrombosis and haemostasis: JTH 18 (4) (2020) 844–  
626 847. doi:10.1111/jth.14768. 698
- 627 [5] H. Han, L. Yang, R. Liu, F. Liu, K.-L. Wu, J. Li, X.-H. Liu, C.-L. Zhu,  
628 Prominent changes in blood coagulation of patients with SARS-CoV-  
629 2 infection, Clinical Chemistry and Laboratory Medicine 58 (7) (2020),  
630 1116–1120. doi:10.1515/cc1m-2020-0188. 702
- 631 [6] X. Bi, Z. Su, H. Yan, J. Du, J. Wang, L. Chen, M. Peng, S. Chen, B. Shen,  
632 J. Li, Prediction of severe illness due to COVID-19 based on an analysis  
633 of initial Fibrinogen to Albumin Ratio and Platelet count, Platelets 31 (5)  
634 (2020) 674–679. doi:10.1080/09537104.2020.1760230. 706
- 635 [7] F. Liu, L. Li, M. Xu, J. Wu, D. Luo, Y. Zhu, B. Li, X. Song, X. Zhou,  
636 Prognostic value of interleukin-6, C-reactive protein, and procalcitonin  
637 in patients with COVID-19, Journal of Clinical Virology: The Official  
638 Publication of the Pan American Society for Clinical Virology 127 (2020),  
639 104370. doi:10.1016/j.jcv.2020.104370. 711
- 640 [8] G. Vaseghi, M. Mansourian, R. Karimi, K. Heshmat-Ghahdarjani,  
641 P. Rouhi, M. Shariati, S. H. Javanmard, Inflammatory markers in Covid-  
642 19 Patients: A systematic review and meta-analysis, medRxiv (2020)  
643 2020.04.29.20084863doi:10.1101/2020.04.29.20084863. 715
- 644 [9] Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of  
645 mortality due to COVID-19 based on an analysis of data of 150 patients,  
646 from Wuhan, China, Intensive Care Medicine 46 (5) (2020) 846–848,  
647 doi:10.1007/s00134-020-05991-x. 719
- 648 [10] B. E. Young, S. W. X. Ong, S. Kalimuddin, J. G. Low, S. Y. Tan, J. Loh,  
649 O.-T. Ng, K. Marimuthu, L. W. Ang, T. M. Mak, S. K. Lau, D. E. An-  
650 derson, K. S. Chan, T. Y. Tan, T. Y. Ng, L. Cui, Z. Said, L. Kurupatham,  
651 M. I.-C. Chen, M. Chan, S. Vasoo, L.-F. Wang, B. H. Tan, R. T. P. Lin,  
652 V. J. M. Lee, Y.-S. Leo, D. C. Lye, Singapore 2019 Novel Coronavirus,  
653 Outbreak Research Team, Epidemiologic Features and Clinical Course  
654 of Patients Infected With SARS-CoV-2 in Singapore, JAMA 323 (15)  
655 (2020) 1488–1494. doi:10.1001/jama.2020.3204. 727
- 656 [11] J. Liu, Y. Liu, P. Xiang, L. Pu, H. Xiong, C. Li, M. Zhang, J. Tan, Y. Xu,  
657 R. Song, M. Song, L. Wang, W. Zhang, B. Han, L. Yang, X. Wang,  
658 G. Zhou, T. Zhang, B. Li, Y. Wang, Z. Chen, X. Wang, Neutrophil-to-  
659 Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coro-  
660 navirus in the Early Stage, medRxiv (2020) 2020.02.10.20021584doi:  
661 10.1101/2020.02.10.20021584. 733
- 662 [12] L. E. Gralinski, A. Bankhead, S. Jeng, V. D. Menachery, S. Proll, S. E-  
663 belisle, M. Matzke, B.-J. M. Webb-Robertson, M. L. Luna, A. K. Shukla,  
664 M. T. Ferris, M. Bolles, J. Chang, L. Aicher, K. M. Waters, R. D. Smith,  
665 T. O. Metz, G. L. Law, M. G. Katze, S. McWeeney, R. S. Baric, Mech-  
666 anisms of severe acute respiratory syndrome coronavirus-induced acute-  
667 lung injury, mBio 4 (4) (Aug. 2013). doi:10.1128/mBio.00271-13. 739
- 668 [13] Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao,  
669 H. Liu, L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao,  
670 F.-S. Wang, Pathological findings of COVID-19 associated with acute res-  
671 piratory distress syndrome, The Lancet Respiratory Medicine 8 (4) (2020),  
672 420–422. doi:10.1016/S2213-2600(20)30076-X. 743
- 673 [14] M. Arentz, E. Yim, L. Klaff, S. Lokhandwala, F. X. Riedo, M. Chong,  
674 M. Lee, Characteristics and Outcomes of 21 Critically Ill Patients With  
675 COVID-19 in Washington State, JAMA 323 (16) (2020) 1612–1614.  
676 doi:10.1001/jama.2020.4326. 744
- 677 [15] N. Wilson, A. Kvalsvig, L. T. Barnard, M. G. Baker, Case-Fatality Risk  
678 Estimates for COVID-19 Calculated by Using a Lag Time for Fatality  
679 - Volume 26, Number 6—June 2020 - Emerging Infectious Diseases  
680 journal - CDC, Emerging Infectious Diseases (2020). doi:10.3201/  
681 eid2606.200320. 745
- 682 [16] H. Barrasa, J. Rello, S. Tejada, A. Martín, G. Balziskueta, C. Vin-  
683 uesa, B. Fernández-Miret, A. Villagra, A. Vallejo, A. San Sebastián,  
684 S. Cabañes, S. Iribarren, F. Fonseca, J. Maynar, Alava COVID-19 Study  
685 Investigators, SARS-CoV-2 in Spanish Intensive Care Units: Early expe-  
686 rience with 15-day survival in Vitoria, Anaesthesia, Critical Care & Pain  
687 Medicine 39 (5) (2020) 553–561. doi:10.1016/j.accpm.2020.04.  
688 001. 746
- 689 [17] L. Wynants, B. V. Calster, G. S. Collins, R. D. Riley, G. Heinze, E. Schuit,  
690 M. M. J. Bonten, D. L. Dahly, J. A. Damen, T. P. A. Debray, V. M. T.  
691 de Jong, M. D. Vos, P. Dhiman, M. C. Haller, M. O. Harhay, L. Henck-  
692 aerts, P. Heus, M. Kammer, N. Kreuzberger, A. Lohmann, K. Luijken,  
693 J. Ma, G. P. Martin, D. J. McLernon, C. L. A. Navarro, J. B. Reitsma,  
694 J. C. Sergeant, C. Shi, N. Skoetz, L. J. M. Smits, K. I. E. Snell, M. Sper-  
695 rin, R. Spijker, E. W. Steyerberg, T. Takada, I. Tzoulaki, S. M. J. van  
696 Kuijk, B. C. T. van Bussel, I. C. C. van der Horst, F. S. van Royen, J. Y.  
697 Verbakel, C. Wallisch, J. Wilkinson, R. Wolff, L. Hooft, K. G. M. Moons,  
698 M. van Smeden, Prediction models for diagnosis and prognosis of covid-  
699 19: Systematic review and critical appraisal, BMJ 369 (2020) m1328.  
700 doi:10.1136/bmj.m1328. 747
- 701 [18] R. Tibshirani, Regression Shrinkage and Selection Via the Lasso, Journal  
702 of the Royal Statistical Society: Series B (Methodological) 58 (1) (1996)  
703 267–288. doi:10.1111/j.2517-6161.1996.tb02080.x. 748
- 704 [19] J. Pironen, M. Paasiniemi, A. Vehtari, Projective inference in high-  
705 dimensional problems: Prediction and feature selection, Electronic Jour-  
706 nal of Statistics 14 (1) (2020) 2155–2197. doi:10.1214/20-EJS1711. 749
- 707 [20] J. C. Marshall, S. Murthy, J. Diaz, N. Adhikari, D. C. Angus, Y. M. Arabi,  
708 K. Baillie, M. Bauer, S. Berry, B. Blackwood, et al., A minimal common  
709 outcome measure set for covid-19 clinical research, The Lancet Infectious  
710 Diseases 20 (8) (2020) e192–e197. 750
- 711 [21] M. van der Schaar Lab, Time series in healthcare: challenges and  
712 solutions, <https://www.vanderschaar-lab.com/time-series-in-healthcare/>  
713 (2022). 751
- 714 [22] C. M. Carvalho, N. G. Polson, J. G. Scott, Handling sparsity via the horse-  
715 shoe, in: Artificial Intelligence and Statistics, PMLR, 2009, pp. 73–80. 752
- 716 [23] Variable selection – A review and recommendations for the practicing  
717 statistician - Heinze - 2018 - Biometrical Journal - Wiley Online Library,  
718 <https://onlinelibrary.wiley.com/doi/full/10.1002/bimj.201700067> (2018). 753
- 719 [24] Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: A  
720 Practical and Powerful Approach to Multiple Testing, Journal of the  
721 Royal Statistical Society. Series B (Methodological) 57 (1) (1995) 289–  
722 300. 754
- 723 [25] J. Taylor, R. J. Tibshirani, Statistical learning and selective inference,  
724 Proceedings of the National Academy of Sciences 112 (25) (2015)  
725 7629–7634. doi:10.1073/pnas.1507583112. 755
- 726 [26] R. Tibshirani, R. Tibshirani, J. Taylor, J. Loftus, S. Reid (Sep 2019).  
727 [link].  
728 URL <https://github.com/selective-inference/R-software> 756
- 729 [27] R. H. Groenwold, Informative missingness in electronic health record sys-  
730 tems: the curse of knowing, Diagnostic and prognostic research 4 (1)  
731 (2020) 1–6. 757
- 732 [28] S. Van Buuren, Flexible imputation of missing data, CRC press, 2018. 758
- 733 [29] D. G. Altman, P. Royston, The cost of dichotomising continuous vari-  
734 ables, BMJ : British Medical Journal 332 (7549) (2006) 1080. 759
- 735 [30] S. R. Knight, A. Ho, R. Pius, I. Buchan, G. Carson, T. M. Drake, J. Dun-  
736 ning, C. J. Fairfield, C. Gamble, C. A. Green, et al., Risk stratification  
737 of patients admitted to hospital with covid-19 using the isaric who clinical  
738 characterisation protocol: development and validation of the 4c mortality  
739 score, bmj 370 (2020). 760
- 740 [31] J. Zhou, S. Lee, X. Wang, Y. Li, W. K. K. Wu, T. Liu, Z. Cao, D. D. Zeng,  
741 K. S. K. Leung, A. K. C. Wai, et al., Development of a multivariable  
742 prediction model for severe covid-19 disease: a population-based study  
743 from hong kong, NPJ digital medicine 4 (1) (2021) 1–9. 761






Figure S1: Heat map displaying missing values across recorded biomarkers. Light blue indicates a value is missing and dark blue indicate it is present




Figure S2: Example biomarker time series for a patient admitted to hospital COVID-19 positive and who subsequently died almost two weeks later.




Figure S3: Example biomarker time series for a patient admitted to hospital with subsequent nosocomial transmission and discharge a week later.




Figure S4: Example biomarker time series for a patient admitted to hospital COVID-19 positive, with subsequent entrance to ICU and death over one month later.

744 [32] E. Carr, R. Bendayan, D. Bean, M. Stammers, W. Wang, H. Zhang,  
 745 T. Searle, Z. Kraljevic, A. Shek, H. T. T. Phan, W. Muret, R. K. Gupta,  
 746 A. J. Shinton, M. Wyatt, T. Shi, X. Zhang, A. Pickles, D. Stahl, R. Zak-  
 747 eri, M. Noursadeghi, K. O'Gallagher, M. Rogers, A. Folarin, A. Karwath,  
 748 K. E. Wickstrøm, A. Köhn-Luque, L. Slater, V. R. Cardoso, C. Bour-  
 749 deaux, A. R. Holten, S. Ball, C. McWilliams, L. Roguski, F. Borca,  
 750 J. Batchelor, E. K. Amundsen, X. Wu, G. V. Gkoutos, J. Sun, A. Pinto,  
 751 B. Guthrie, C. Breen, A. Douiri, H. Wu, V. Curcin, J. T. Teo, A. M.  
 752 Shah, R. J. B. Dobson. Evaluation and improvement of the National Early  
 753 Warning Score (NEWS2) for COVID-19: A multi-hospital study, *BMC*  
 754 *Medicine* 19 (1) (2021) 23. doi:10.1186/s12916-020-01893-3.




Figure S5: Example biomarker time series for a patient admitted to hospital and ICU, with subsequent nosocomial transmission and discharge about one week later.

755 **Supplementary materials**




Figure S6: Example biomarker time series for a patient with two hospital admissions and testing COVID-19 positive on the first, with discharge almost two weeks after second admission.




Figure S7: Distribution of D-Dimer readings with clinical classification requiring age and gender bands

Biomarker	Binary Categorical Variable	P-Value	Odds Ratio CI [2.5%, 97.5%]
<b>Demographics / Other</b>			
Age	-	6.30E-05	1.04 [1.02, 1.06]
Gender	Female	0.43	1.21 [0.75, 1.97]
<b>Blood Clotting Tests</b>			
Activated partial thromboplastin time	Mild	0.07	2.79 [0.93, 8.35]
	Moderate	0.99	3.23E+07 [0, Inf]
	Not Taken	0.50	0.45 [0.05, 4.51]
Prothrombin Time	Abnormal	0.16	2.02 [0.75, 5.44]
	Not Taken	0.46	2.38 [0.24, 23.86]
<b>Blood Gas Tests</b>			
Carbon Dioxide	Abnormal	0.80	1.13 [0.44, 2.95]
	Not Taken	NA	NA
Lactate	Abnormal	0.63	0.67 [0.13, 3.34]
	Not Taken	0.02	0.16 [0.04, 0.72]
Oxygen	Abnormal	0.95	1.05 [0.26, 4.15]
	Not Taken	NA	NA
Bicarbonate Excess	Abnormal	0.24	1.48 [0.76, 2.87]
	Not Taken	0.99	0 [0, Inf]
pH acid/base scale	Abnormal	0.13	1.59 [0.87, 2.91]
	Not Taken	0.99	9.4E06 [0, Inf]
<b>Coinfection</b>			
Blood Culture	TRUE	0.99	0 [0, Inf]
Respiratory	TRUE	0.36	2.71 [0.32, 22.69]
Urine	TRUE	0.43	0.45 [0.06, 3.24]
Viral	TRUE	0.02	16.64 [1.7, 162.66]
<b>Diabetes</b>			
Glucose	Abnormal	0.36	1.55 [0.61, 3.92]
	Not Taken	0.60	0.84 [0.44, 1.61]
<b>Full Blood Count Tests</b>			
Hemoglobin	Mild	0.05	1.76 [1.01, 3.09]
	Moderate	0.99	1.01 [0.40, 2.51]
	Severe	0.15	4.62 [0.58, 37.05]
	Not Taken	0.99	1.3E9 [0, Inf]
Platelet Count	Mild	0.01	2.8 [1.33, 5.90]
	Moderate	0.03	5.81 [1.21, 28.03]
	Severe	0.10	20.44 [0.57, 734.84]
	Not Taken	0.99	0 [0, Inf]
Lymphocytes	Mild	0.12	1.98 [0.83, 4.73]
	Moderate	0.23	1.81 [0.69, 4.76]
	Severe	0.14	2.61 [0.74, 9.22]
	Not Taken	NA	NA
Neutrophils	Mild	0.02	0.05 [4E-3, 0.59]
	Moderate	0.73	0.22 [3.1E-5, 1.4E3]
	Severe	0.38	1.45 [0.63, 3.32]
	Not Taken	NA	NA
Neutrophil - Lymphocyte Ratio	Mild	0.82	1.1 [0.48, 2.52]
	Moderate	0.80	1.15 [0.39, 3.44]
	Severe	0.41	1.89 [0.41, 8.69]
	Not Taken	NA	NA
White Cell Count	Mild	0.72	0.83 [0.29, 2.38]
	Moderate	0.73	0.21 [2.5E-5, 1.6E3]
	Severe	0.83	1.11 [0.43, 2.83]
	Not Taken	NA	NA
<b>Urea &amp; Electrolytes Tests</b>			
C-Reactive Protein	Abnormal	0.07	4.46 [0.91, 21.93]
	Not Taken	0.94	0.90 [0.07, 12.34]
Estimated Glomerular Filtration Rate	Abnormal	0.41	0.72 [0.33, 1.58]
	Not Taken	0.04	0.25 [0.06, 0.95]
Urea	Abnormal	3.71E-04	2.74 [1.57, 4.77]
	Not Taken	0.95	0.94 [0.11, 7.76]
<b>Investigatory Tests</b>			
Brain / B-type natriuretic peptide	Abnormal	0.72	1.47 [0.18, 11.76]
	Not Taken	0.81	1.24 [0.21, 7.40]
D-Dimer	Abnormal	0.31	0.42 [0.08, 2.24]
	Not Taken	0.23	0.37 [0.07, 1.89]
Ferritin	Mild	0.10	5.65 [0.71, 45.00]
	Moderate	0.61	1.52 [0.30, 7.58]
	Severe	0.84	1.30 [0.10, 17.54]
	Not Taken	0.63	1.30 [0.45, 3.72]
Fibrinogen	Mild	0.21	11.93 [0.26, 552.59]
	Severe	0.42	0.26 [0.01, 6.77]
	Not Taken	0.92	1.07 [0.27, 4.22]
Lactate dehydrogenase	Mild	0.13	14.88 [0.46, 477.41]
	Moderate	0.31	5.41 [0.20, 145.69]
	Severe	0.48	4.20 [0.08, 217.62]
	Not Taken	0.61	2.13 [0.12, 39.40]
Troponin-T	Abnormal	0.68	1.31 [0.37, 4.65]
	Not Taken	0.58	1.40 [0.43, 4.53]
<b>Intercept</b>			
Intercept	-	0.004	0.001 [0.0, 0.11]




Figure S9: Model calibration depicting a standard GLM model trained on: (Top) all data and tested on all data (Middle); training data (n=590) and tested on the same; (Bottom) training data and tested on validation data (n=293). A well calibrated model should evenly distribute outcome probabilities, i.e. be close to unity.




Figure S10: Frequency of LASSO logistic regression variables having a coefficient greater or less than 0. Red and black lines indicate thresholds for 20% and 50% frequency.






Figure S11: Heatmap representation of the LOO variable selection output from Bayesian projective prediction ranking predictive power as a function in change of AUC. The color of an individual cell shows the proportion of times in the LOO process a variable was chosen at that particular rank of predictive strength. Note this demonstrates a reduced 15-biomarker model (51 variables total), where biomarkers that had 'Test Not Taken' ranked as their most important predictive element were removed from the model.

Solution Terms	AUC	Difference	ELPD LOO	Standard Error	Difference	Standard Error
<NA>	0	-0.8	-358.5	9.7	-61.6	10.7
UreaAbnormal	0.5	-0.3	-326.3	11.4	-29.4	8.3
poctLACNA	0.6	-0.2	-310.6	12.2	-13.6	6.4
O2NA	0.6	-0.2	-310.6	12.2	-13.6	6.4
CO2NA	0.6	-0.2	-310.5	12.1	-13.6	6.3
Age	0.8	0	-302.2	11.9	-5.3	5
PTAbnormal	0.8	0	-299.2	12	-2.2	4.3
NLRSevere	0.8	0	-307.6	12.3	-10.7	4
LDHNA	0.8	0	-304.7	12.5	-7.8	3.7
poctpHAbnormal	0.8	0	-302.3	12.4	-5.4	3.4
LymphocytesSevere	0.8	0	-302.9	12.4	-5.9	3.4
APTTMild	0.8	0	-301.4	12.4	-4.5	3.4
eGFRAbnormal	0.8	0	-299	12.4	-2	3.3
NeutrophilsSevere	0.8	0	-301.8	12.6	-4.8	3.1
APTTModerate	0.8	0	-302.5	12.8	-5.6	3
FERNA	0.8	0	-304.7	12.8	-7.8	2.9
fibNA	0.8	0	-302.4	12.8	-5.4	2.8
CRPAbnormal	0.8	0	-303.1	12.7	-6.2	2.8
CO2Abnormal	0.8	0	-301.2	12.8	-4.3	2.7
DDMAbnormal	0.8	0	-302.4	12.7	-5.5	2.6
HBSevere	0.8	0	-302.9	12.8	-6	2.6

Figure S12: Summary statistics of Bayesian projective prediction ranking the contribution of each variable by change in AUC and expected log-predictive density (ELPD)

Biomarker	Binary Categorical Variable	Bayesian Horshoe Odds Ratios CI [2.5%, 97.5%]	Projective Prediction 3-Biomarker Model Odds Ratios CI [2.5%, 97.5%]
<b>Demographics / Other</b>			
Age	-	1.03 [1.02, 1.05]	1.02 [1, 1.03]
Gender	Female	0.99 [0.74, 1.3]	
<b>Blood Clotting Tests</b>			
Activated partial thromboplastin time	Mild	1.57 [0.87, 4.63]	
	Moderate	3.24 [0.81, 112.13]	
	Not Taken	0.93 [0.55, 1.32]	
Prothrombin Time	Abnormal	1.66 [0.91, 4.18]	2.32 [1.15, 4.61]
	Not Taken	0.99 [0.64, 1.55]	0.63 [0.41, 0.9]
<b>Blood Gas Tests</b>			
Carbon Dioxide	Abnormal	1.05 [0.69, 1.81]	
	Not Taken	0.64 [0.13, 1.6]	
Lactate	Abnormal	0.89 [0.36, 1.53]	
	Not Taken	0.63 [0.13, 1.58]	
Oxygen	Abnormal	1.1 [0.66, 2.52]	
	Not Taken	0.63 [0.13, 1.56]	
Bicarbonate Excess	Abnormal	1.13 [0.84, 1.91]	
	Not Taken	1.1 [0.68, 2.17]	
pH acid/base scale	Abnormal	1.3 [0.91, 2.31]	
	Not Taken	1.17 [0.78, 2.54]	
<b>Coinfection</b>			
Blood Culture	TRUE	0.6 [0.04, 1.4]	
Respiratory	TRUE	1.1 [0.56, 3.19]	
Urine	TRUE	0.94 [0.39, 1.72]	
Viral	TRUE	1.81 [0.77, 14.79]	
<b>Diabetes</b>			
Glucose	Abnormal	1.1 [0.76, 2.01]	
	Not Taken	0.96 [0.66, 1.3]	
<b>Full Blood Count Tests</b>			
Hemoglobin	Mild	1.11 [0.85, 1.7]	
	Moderate	1 [0.63, 1.54]	
	Severe	1.57 [0.77, 8.07]	
	Not Taken	1.3 [0.55, 8.27]	
Platelet Count	Mild	1.35 [0.89, 2.83]	
	Moderate	1.58 [0.83, 6.12]	
	Severe	1.41 [0.64, 11.32]	
	Not Taken	0.97 [0.34, 2.29]	
Lymphocytes	Mild	1.05 [0.76, 1.6]	
	Moderate	1.02 [0.75, 1.48]	
	Severe	1.2 [0.84, 2.35]	
	Not Taken	1.31 [0.56, 8.86]	
Neutrophils	Mild	0.66 [0.13, 1.27]	
	Moderate	1 [0.33, 2.96]	
	Severe	1.14 [0.82, 1.95]	
	Not Taken	1.31 [0.57, 8.9]	
Neutrophil - Lymphocyte Ratio	Mild	1.04 [0.77, 1.55]	1.32 [0.92, 2.29]
	Moderate	1.08 [0.79, 1.78]	1.98 [1.34, 3.38]
	Severe	1.38 [0.86, 3.41]	2.55 [1.5, 5.34]
	Not Taken	1.31 [0.57, 8.84]	3.22 [0.94, 14.32]
White Cell Count	Mild	0.91 [0.48, 1.35]	
	Moderate	1.04 [0.37, 3.61]	
	Severe	1.12 [0.78, 2]	
	Not Taken	1.29 [0.55, 8.15]	
<b>Urea &amp; Electrolytes Tests</b>			
C-Reactive Protein	Abnormal	2.04 [0.93, 7.61]	
	Not Taken	1.11 [0.55, 3.54]	
Estimated Glomerular Filtration Rate	Abnormal	1.03 [0.71, 1.6]	
	Not Taken	0.72 [0.26, 1.16]	
Urea	Abnormal	2.83 [1.72, 4.65]	3.28 [2.2, 5.2]
	Not Taken	1.07 [0.56, 2.53]	0.84 [0.25, 1.81]
<b>Investigatory Tests</b>			
Brain / B-type natriuretic peptide	Abnormal	1.05 [0.64, 1.99]	
	Not Taken	0.95 [0.53, 1.49]	
D-Dimer	Abnormal	1.07 [0.66, 2.08]	
	Not Taken	0.85 [0.4, 1.3]	
Ferritin	Mild	1.43 [0.75, 6.87]	
	Moderate	1.07 [0.65, 2.14]	
	Severe	1.01 [0.44, 2.35]	
	Not Taken	0.93 [0.56, 1.34]	
Fibrinogen	Mild	1.32 [0.61, 8.49]	
	Severe	0.92 [0.26, 2.21]	
	Not Taken	0.87 [0.39, 1.37]	
Lactate dehydrogenase	Mild	1.29 [0.7, 5.43]	
	Moderate	1.07 [0.56, 2.51]	
	Severe	1.05 [0.47, 2.96]	
	Not Taken	0.71 [0.24, 1.22]	
Troponin-T	Abnormal	1.01 [0.68, 1.55]	
	Not Taken	1.02 [0.71, 1.57]	
<b>Intercept</b>			
Intercept	-	0.04 [0.0, 0.28]	0.05 [0.02, 0.11]

Figure S13: Odds ratios for full Bayesian model and reduced 3-biomarker model via projective prediction




Figure S14: Model calibration depicting Projective Prediction 3-biomarker model tested on: (Top) training data (n=590); (Bottom) validation data (n=293). Note the models do not have points for each of the 10 probability bins because some ranges, e.g. 0.9-1.0 had no patients in this band as judged by the model output. A well calibrated model should evenly distribute outcome probabilities, i.e. be close to unity.